- Home
- ATNI vs ESPR Comparison
ATNI vs ESPR Comparison
Compare ATNI & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNI
- ESPR
- Stock Information
- Founded
- ATNI 1987
- ESPR 2008
- Country
- ATNI United States
- ESPR United States
- Employees
- ATNI N/A
- ESPR N/A
- Industry
- ATNI Telecommunications Equipment
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- ATNI Telecommunications
- ESPR Health Care
- Exchange
- ATNI Nasdaq
- ESPR Nasdaq
- Market Cap
- ATNI 328.8M
- ESPR 305.0M
- IPO Year
- ATNI 1991
- ESPR 2013
- Fundamental
- Price
- ATNI $20.27
- ESPR $1.41
- Analyst Decision
- ATNI Strong Buy
- ESPR Buy
- Analyst Count
- ATNI 2
- ESPR 7
- Target Price
- ATNI $31.00
- ESPR $6.36
- AVG Volume (30 Days)
- ATNI 93.2K
- ESPR 4.3M
- Earning Date
- ATNI 03-04-2025
- ESPR 03-04-2025
- Dividend Yield
- ATNI 4.73%
- ESPR N/A
- EPS Growth
- ATNI N/A
- ESPR N/A
- EPS
- ATNI N/A
- ESPR N/A
- Revenue
- ATNI $729,075,000.00
- ESPR $332,314,000.00
- Revenue This Year
- ATNI $3.02
- ESPR $5.51
- Revenue Next Year
- ATNI $0.27
- ESPR $1.42
- P/E Ratio
- ATNI N/A
- ESPR N/A
- Revenue Growth
- ATNI N/A
- ESPR 185.66
- 52 Week Low
- ATNI $14.74
- ESPR $1.35
- 52 Week High
- ATNI $33.72
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- ATNI 49.75
- ESPR 34.46
- Support Level
- ATNI $20.94
- ESPR $1.47
- Resistance Level
- ATNI $22.23
- ESPR $1.75
- Average True Range (ATR)
- ATNI 1.14
- ESPR 0.10
- MACD
- ATNI -0.31
- ESPR -0.01
- Stochastic Oscillator
- ATNI 9.02
- ESPR 15.00
About ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.